Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod® 5 Pods in the U.S.

Key Terms

medical device correction regulatory

A medical device correction is an action taken by a manufacturer or regulator to fix a safety or performance problem in an already-distributed medical device, such as a repair, software update, label change, or retrofit. It matters to investors because corrections can signal safety risk, trigger costs, regulatory scrutiny, lost sales or reputational damage—similar to a software patch or auto recall that interrupts normal business and may affect future revenue and liability exposure.

continuous glucose monitoring (cgm) medical

A continuous glucose monitoring (CGM) system is a small wearable sensor and transmitter that measures a person’s blood sugar levels continuously and sends real‑time readings to a display or smartphone app, reducing the need for finger‑prick tests. Investors care because CGM shifts diabetes care toward ongoing device sales, subscriptions and data services; wider patient adoption, insurance coverage and better accuracy can drive steady revenue and create opportunities for new health products and analytics, similar to moving from one‑off purchases to a subscription service.

diabetic ketoacidosis (dka) medical

A life-threatening complication of diabetes where very high blood sugar causes the body to burn fat for fuel, producing acidic waste that disrupts normal organs—think of a car engine starving for the right fuel and filling the system with harmful smoke. It matters to investors because cases can trigger safety alerts, regulatory scrutiny, product recalls or costly lawsuits, affect clinical trial outcomes, and influence a healthcare company's reputation and future revenue.

u.s. food and drug administration (fda) regulatory

The U.S. Food and Drug Administration (FDA) is a government agency responsible for protecting public health by ensuring the safety and effectiveness of food, medicines, vaccines, and other health-related products. For investors, the FDA’s decisions can significantly impact companies in the healthcare and food industries, as approval or rejection of products can influence a company's success and stock performance.

• Medical Device Correction impacts only specific lots of Omnipod® 5 Pods
• Customers can visit omnipod.com/check-pods to check lot numbers and request replacement Pods at no cost
• All other Omnipod® 5 Pods and Omnipod® products remain safe to use

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”) today initiated a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods after identifying a manufacturing issue through its ongoing product monitoring. This action applies to specific identified lots distributed in the United States, and all other Omnipod® 5 Pods and Omnipod® products remain safe to use.

Insulet identified that certain Pods from specific lots may have a small tear in the internal tubing that delivers insulin. If this occurs, insulin may leak inside the Pod instead of being fully infused into the body as intended.

If insulin is not delivered properly, users may experience high blood glucose levels due to under-delivery of insulin. In the most severe cases, prolonged and persistent high blood glucose levels can lead to diabetic ketoacidosis (DKA), a serious medical condition that requires prompt medical treatment.

Insulet has received 18 reports of serious adverse events associated with high blood glucose levels, including hospitalization and DKA. No deaths have been reported.

This issue does not affect continuous glucose monitoring (CGM) systems or CGM readings.

Following its investigation, Insulet has implemented updates to its manufacturing processes and quality controls to strengthen detection and prevention and further support the integrity of its products. The Pods involved in this correction represent approximately 1.5% of annual Omnipod® 5 pod production globally.

Insulet continues to manufacture and ship Omnipod® 5 Pods and does not anticipate disruption to customer shipments, product availability, or new patient starts.

The U.S. Food and Drug Administration (FDA) has been notified of this action. Patient safety and product quality remain Insulet’s highest priorities.

Important Information for Omnipod® 5 Users

Customers should visit omnipod.com/check-pods to confirm whether their Pod lot number is included in this voluntary Medical Device Correction and request replacement Pods at no cost.

If a Pod from an affected lot is currently in use, customers should discontinue use and replace it with a Pod from an unaffected lot.

Customers who have questions or need assistance may contact Insulet Product Support at 1-800-641-2049 (available 24/7) or use the live agent chat at omnipod.com/current-podders.

About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod® product platform. The Omnipod® Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod® 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod® 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod® technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit insulet.com and omnipod.com.

Forward-Looking Statement:
This press release includes certain forward-looking statements within the meaning of the Private Litigation Securities Reform Act of 1995, as amended. Forward-looking statements relate to future events, including statements concerning the Company’s plans or expectations regarding the voluntary medical device correction and effects of the voluntary medical device correction on the Company’s business, operations, and financial performance or guidance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond the Company’s control, that may cause the actual results, performance or achievements of the Company to be materially different from its current expectations, assumptions, plans, guidance, estimates and projections, including (but not limited to) the financial, operational, and reputational impact and costs of the voluntary medical device correction, future actions by the FDA and other regulatory bodies, the possibility that the voluntary medical device correction could subject the Company to disputes, claims or proceedings that may adversely affect its business and financial operation and other factors detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including those discussed under “Risk Factors” in the Company’s Form 10-K for the year ended December 31, 2025. The Company encourages you to consider all of these risks, uncertainties and other factors carefully in evaluating the forward-looking statements contained in this press release. The forward-looking statements made in this press release are made only as of the date of this press release, and the Company undertakes no obligation to update them to reflect subsequent events or circumstances except as required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260312976912/en/

Media:

Cristal Downing

Chief Corporate Affairs Officer

pr@insulet.com

Investor Relations:

Clare Trachtman

Vice President, Investor Relations

ir@insulet.com

Source: Insulet Corporation, Inc.